
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio is on a positive trajectory with a strong management team, best-in-class products, and structural tailwinds. While the recent updates from the management team have led to a lowered top-line guidance, the company's up-sized debt capacity and equity raise demonstrate a commitment to long-term growth. However, execution and stability within the sales force will be crucial for TELA to continue to take market share and achieve operational leverage.
Bears say
TELA Bio is facing challenges in its sales team reorganization and go-to-market strategy, leading to lowered revenue guidance for FY26 by nearly half of previous expectations. While the company has solid unit volume growth and a renewed territory strategy, their reliance on reimbursement and potential for future losses and dilution remains a concern. Additionally, there is still much to prove in terms of execution and accelerating business momentum, despite the company's strong product portfolio. These factors contribute to the negative outlook for TELA Bio's stock.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares